ESPOO, FINLAND - Aug 18, 2014 - BC Platforms has been qualified
to receive Tekes funding for its R&D program for its
large-scale clinical and genomic R&D solutions. The company has
set a tight focus on data integration and interoperability tools
and interfaces. The BC Operating System facilitates management of
truly diverse resources in a scattered data landscape. Data
recycling, security, and research reproducibility are the driving
principles behind the development of BC Platforms' products.
Tekes, the Finnish Funding Agency for Innovation, has a crucial
role in helping the company to detach resources for a two-year
development project. With a market entry in sight in year 2015, the
company will roll out a completely new infrastructure to compete
ever-increasing research data overflow. The aim is to bring high
performance analysis management tools to the reach of biological,
medical, and veterinary R&D projects of all sizes.
We are very pleased with the funding decision. This funding
ensures that the development of our core product, BC Operating
System, will meet the requirements of the most demanding
infrastructures in the future, says Anni Ahonen-Bishopp, R&D
Director of BC Platforms. The funding also allows us to invest in
our growth strategy, CEO of BC Platforms, Tero Silvola, adds.
The data integration and analysis management platform will be
available as a pure cloud solution, as an in-house server platform,
or as a hybrid of the two. The platform supports EHR data, legacy
biobank collections, phenotype, genomic, transcriptomic, and NGS
-derived data. Although analysis and reporting tools can be freely
customized, three major workflows will be optimized for highest and
most stable performance: NGS analysis, genome wide associations,
and imputation of genotypes.
The new platform will have strategic pilot projects at the end
Tero Silvola, CEO, tel.
+358 40 590 5733, email:
Anni Ahonen-Bishopp, Director
R&D, tel. +44 7902
About BC Platforms
BC Platforms Ltd (est. in 1997) develops clinical and genomic
data integration and analysis software. Their software is used in
genomic research, genetic counseling, pharmacogenomics research,
preventive and personalized medicine and biobanking. They provide
customized solutions for pharma/biotech companies that utilize
genomic data in their R&D. BC Platforms serves a wide
international customer base in 18 countries and three continents.
Their customers consist of top-tier research groups, international
cohort studies, biobanks and major pharmaceutical companies
collecting and analyzing genotype and phenotype data. The company
headquarters is located in Finland and they have sales
representation in Canada, England, Switzerland and the